Omnicell (OMCL) Misses Q3 EPS by 1c
Get Alerts OMCL Hot Sheet
Revenue Growth %: -18.6%
Financial Fact:
Selling, general and administrative: 61.32M
Today's EPS Names:
RUSHA, SEIC, OSBC, More
Join SI Premium – FREE
Omnicell (NASDAQ: OMCL) reported Q3 EPS of $0.40, $0.01 worse than the analyst estimate of $0.41. Revenue for the quarter came in at $176.7 million versus the consensus estimate of $179.75 million.
"Omnicell completed another strong quarter marked by record revenues and market share gains," said Randall Lipps, Omnicell President, CEO and Chairman. "Omnicell's continued growth is the result of successfully broadening our product portfolio, expanding the markets we participate in, and partnering with our customers to address medication management across the full continuum of patient care. The Company is well positioned to take advantage of the great opportunities ahead," Mr. Lipps added.
For earnings history and earnings-related data on Omnicell (OMCL) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Amphenol (APH) Tops Q1 EPS by 7c, offers guidance
- Amphenol (APH) Reports Q1, Announces $2B Share Buyback
- Bok Financial Corp (BOKF) Misses Q1 EPS by 27c
Create E-mail Alert Related Categories
Earnings, Management CommentsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!